24-09-2017 22:00 via prnewswire.com

Long-term survival rates more than double previous estimates for locally advanced lung cancer

SAN DIEGO, Sept. 24, 2017 /PRNewswire-USNewswire/ -- Long-term results of a phase III clinical trial indicate that survival rates for patients receiving chemoradiation for unresectable, locally advanced non-small cell lung cancer (NSCLC) may be more than twice as high as previous...
Read more »